search
Back to results

Safety and Efficacy of a Novel Carpal Tunnel Tissue Manipulation Device in Treating Carpal Tunnel Syndrome

Primary Purpose

Carpal Tunnel Syndrome

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Carpal Tunnel Tissue Manipulation Device (CTMD)
Sponsored by
Pressure Profile Systems, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Carpal Tunnel Syndrome

Eligibility Criteria

21 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  1. male or female, ages 21-65 and in good general health;
  2. subject diagnosed with mild to severe carpal tunnel syndrome (CTS) (AANEM criteria for CTS)

    • mild CTS: prolonged distal sensory latency with ± decreased sensory amplitude
    • moderate CTS: abnormal median sensory latency with prolongation of the distal motor latency
    • severe CTS: prolonged motor and sensory distal peak latencies either with a low or absent SNAP or CMAP
  3. bilateral CTS accepted (either mild, moderate or severe CTS bilaterally), however, more involved wrist (via NCS) used as "study" wrist;
  4. Boston Carpal Tunnel Questionnaire (BCTQ) Symptoms Score ≥ 2;
  5. women of childbearing potential must be willing to practice effective contraception for the duration of the study (i.e., abstinence, condoms or diaphragm with spermicide, IUD, or birth control pills [BCP]);

    NOTE: Females on birth control pills (BCP) must be stable on the same type and dose of pill for at least three months prior to entering the study and must not change the type of BCP or dosing regimen during the study. Those who have discontinued using BCPs in favor of another form of contraception must have discontinued BCP usage at least 3 months prior to the start of the study.

  6. women of child bearing potential must have a negative urine pregnancy test at the Baseline Visit (Visit 1, Day 0) and must not be lactating; and
  7. willingness to follow protocol requirements, including signing an informed consent and health information release forms, attending routine follow-up visits and completing questionnaires.

Exclusion Criteria

  1. known sensitivity to adhesives or glue;
  2. history of diabetes mellitus;
  3. history of thyroid disease;
  4. history of prior wrist fractures;
  5. known to be easily bruised (hematoma);
  6. concurrent use of blood thinners;
  7. history of connective tissue disease;
  8. diagnosed with superimposed peripheral neuropathy;
  9. history of cervical radiculopathy;
  10. diagnosed with purely ulnar paresthesias;
  11. history of ulnar neuropathy;
  12. history of brachial plexopathy;
  13. diagnosed with pronator teres syndrome;
  14. history of polyneuropathy;
  15. uncontrolled systemic disease;
  16. history of any mass, tumor, severe trauma or deformity of the hand or wrist;
  17. previous surgery of the hand or wrist;
  18. history of prior carpal tunnel release;
  19. current use of any splinting or bracing medical device for CTS;
  20. currently taking any medication therapy that could cause a focal or generalized neuropathy (e.g., antiepileptics, statins, chemotherapeutic or antiarrhythmic);
  21. history of any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results;
  22. concomitant use of systemic medication(s) or therapy that may have a substantial effect on CTS condition, unless such medication(s) or therapy has/have been used for a minimum of 3 months prior to study enrollment, is/are expected to remain constant throughout the course of the study and is/are considered necessary for a subjects' welfare;
  23. females who are pregnant, nursing, or planning a pregnancy or who are of childbearing potential and not using a reliable method of contraception;
  24. inability to give informed consent; and
  25. concurrent participation or prior participation in any investigation drug or device study within the last 30 days prior to the Baseline Visit (Visit 1).

Sites / Locations

  • Mission Pain and Spine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Carpal Tunnel Medical Device (CTMD)

Arm Description

Carpal Tunnel Tissue Manipulation Device (CTMD)

Outcomes

Primary Outcome Measures

Change in SSS of the BCTQ at 28 Days vs Baseline
The primary efficacy variable is the decrease in Symptom Severity Scale (SSS) score of the Boston Carpal Tunnel Questionnaire (BCTQ). The SSS is a patient-reported measure of the severity of the patient's symptoms caused by carpal tunnel syndrome, on a scale of 1 (no symptoms) to 5 (worst symptoms).

Secondary Outcome Measures

Change in SSS of the BCTQ 2 Month Post-treatment vs Baseline
The secondary efficacy variable is the decrease in Symptoms Severity Scale (SSS) score of the Boston Carpal Tunnel Questionnaire (BCTQ) obtained 2 months after the 28-day CTMD treatment period compared to the Baseline SSS score.

Full Information

First Posted
March 25, 2015
Last Updated
October 24, 2017
Sponsor
Pressure Profile Systems, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02534493
Brief Title
Safety and Efficacy of a Novel Carpal Tunnel Tissue Manipulation Device in Treating Carpal Tunnel Syndrome
Official Title
Safety and Efficacy of a Novel Carpal Tunnel Tissue Manipulation Device in Treating Carpal Tunnel Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
October 2017
Overall Recruitment Status
Completed
Study Start Date
April 2015 (undefined)
Primary Completion Date
September 2016 (Actual)
Study Completion Date
September 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pressure Profile Systems, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A single-center, prospective, non-randomized study to evaluate the safety and efficacy of a novel carpal tunnel tissue manipulation device in treating symptoms and decreased physical function in subjects previously diagnosed with mild to severe carpal tunnel syndrome (CTS).
Detailed Description
A single-center, prospective, non-randomized study to evaluate the safety and efficacy of a novel carpal tunnel tissue manipulation device in treating symptoms and decreased physical function in subjects previously diagnosed with mild to severe carpal tunnel syndrome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carpal Tunnel Syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Masking Description
open label
Allocation
N/A
Enrollment
11 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Carpal Tunnel Medical Device (CTMD)
Arm Type
Experimental
Arm Description
Carpal Tunnel Tissue Manipulation Device (CTMD)
Intervention Type
Device
Intervention Name(s)
Carpal Tunnel Tissue Manipulation Device (CTMD)
Other Intervention Name(s)
Wrist-Aid
Intervention Description
This piece of rigid, shaped, biocompatible plastic (polypropylene) rated for skin contact and a strong but safe hypoallergenic biocompatible medical adhesive which bonds the skin over the carpal tunnel to the plastic piece for a duration of 2-14 hours.
Primary Outcome Measure Information:
Title
Change in SSS of the BCTQ at 28 Days vs Baseline
Description
The primary efficacy variable is the decrease in Symptom Severity Scale (SSS) score of the Boston Carpal Tunnel Questionnaire (BCTQ). The SSS is a patient-reported measure of the severity of the patient's symptoms caused by carpal tunnel syndrome, on a scale of 1 (no symptoms) to 5 (worst symptoms).
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Change in SSS of the BCTQ 2 Month Post-treatment vs Baseline
Description
The secondary efficacy variable is the decrease in Symptoms Severity Scale (SSS) score of the Boston Carpal Tunnel Questionnaire (BCTQ) obtained 2 months after the 28-day CTMD treatment period compared to the Baseline SSS score.
Time Frame
2 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria male or female, ages 21-65 and in good general health; subject diagnosed with mild to severe carpal tunnel syndrome (CTS) (AANEM criteria for CTS) mild CTS: prolonged distal sensory latency with ± decreased sensory amplitude moderate CTS: abnormal median sensory latency with prolongation of the distal motor latency severe CTS: prolonged motor and sensory distal peak latencies either with a low or absent SNAP or CMAP bilateral CTS accepted (either mild, moderate or severe CTS bilaterally), however, more involved wrist (via NCS) used as "study" wrist; Boston Carpal Tunnel Questionnaire (BCTQ) Symptoms Score ≥ 2; women of childbearing potential must be willing to practice effective contraception for the duration of the study (i.e., abstinence, condoms or diaphragm with spermicide, IUD, or birth control pills [BCP]); NOTE: Females on birth control pills (BCP) must be stable on the same type and dose of pill for at least three months prior to entering the study and must not change the type of BCP or dosing regimen during the study. Those who have discontinued using BCPs in favor of another form of contraception must have discontinued BCP usage at least 3 months prior to the start of the study. women of child bearing potential must have a negative urine pregnancy test at the Baseline Visit (Visit 1, Day 0) and must not be lactating; and willingness to follow protocol requirements, including signing an informed consent and health information release forms, attending routine follow-up visits and completing questionnaires. Exclusion Criteria known sensitivity to adhesives or glue; history of diabetes mellitus; history of thyroid disease; history of prior wrist fractures; known to be easily bruised (hematoma); concurrent use of blood thinners; history of connective tissue disease; diagnosed with superimposed peripheral neuropathy; history of cervical radiculopathy; diagnosed with purely ulnar paresthesias; history of ulnar neuropathy; history of brachial plexopathy; diagnosed with pronator teres syndrome; history of polyneuropathy; uncontrolled systemic disease; history of any mass, tumor, severe trauma or deformity of the hand or wrist; previous surgery of the hand or wrist; history of prior carpal tunnel release; current use of any splinting or bracing medical device for CTS; currently taking any medication therapy that could cause a focal or generalized neuropathy (e.g., antiepileptics, statins, chemotherapeutic or antiarrhythmic); history of any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results; concomitant use of systemic medication(s) or therapy that may have a substantial effect on CTS condition, unless such medication(s) or therapy has/have been used for a minimum of 3 months prior to study enrollment, is/are expected to remain constant throughout the course of the study and is/are considered necessary for a subjects' welfare; females who are pregnant, nursing, or planning a pregnancy or who are of childbearing potential and not using a reliable method of contraception; inability to give informed consent; and concurrent participation or prior participation in any investigation drug or device study within the last 30 days prior to the Baseline Visit (Visit 1).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frank J. King, M.D.
Organizational Affiliation
Mission Pain and Spine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mission Pain and Spine
City
Mission Viejo
State/Province
California
ZIP/Postal Code
92691
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of a Novel Carpal Tunnel Tissue Manipulation Device in Treating Carpal Tunnel Syndrome

We'll reach out to this number within 24 hrs